Glutamate (Glu) immunocytochemistry has been widely used to identify presumed gluergic neurons and synapses, but several problems related to the fact that Glu is both a synaptic transmitter and a compound used for metabolic purposes are d unsolved. One of these concerns the intease perikarllal staining observed in perfusion-fued tissue. Phosphateactivated glutaminase, a key enzyme for the synthesis of releasable glutamate, is inhibited by the diazoketone 6-diazo-5-oxo-~-norleucine (DON), which greatly reduces glutamate release. In the ptesent experiments, DON was either injected intraparenchymally or applied epipially to the sensorimotor cortex of adult Sprague-Dawley rats at concentrations of 0.25-1 mM. Both intrapenchymal and epipial applications of the chemical abolished Glu immunoreactivity in neuron
This approach has since become widely used to study the chemical anatomy of presumptive Glu-ergic neurons, synapses, and pathways in many central nervous system (CNS) structures (for review see Petrusz and Rustioni, 1989) . Several studies have now clearly established that both pre-and post-embedding electron microscopy of sections immunocytochemically stained with anti-Glu sera are reliable tools for studying Glu-ergic axon terminals (DeBiasi and Rustioni, 1990; Conti et al., 1989; Dori et al., 1989; DeFelipe et al., 1988; Ottersen, 1987 Ottersen, ,1989 . However, the suitability of Glu immunostaining as a reliable indicator of Glu-ergic neurons is a subject of considerable debate, since the main light microscopic feature of pre-embedding Glu immunostaining of perfusion-fixed tissue is the presence of intense perikaryal labeling (e.g., Conti et al., 1987a; Ottersen and Storm-Mathisen, 1984) , an observation that is apparently hardly reconcilable with the widely accepted notion that transmitter Glu is synthesized at the nerve terminal (Fonnum, 1991) . In their review, Petrusz and Rustioni (1989) wrote: "It seems prudent to regard strong and consistent staining in neuronal cell bodies (perikarya) as a reflection of metabolic pools and, similarly, strong and consistent staining in nerve terminals, as a reflection of transmitters pools" (see also Ottersen and Storm-Mathisen, 1984) . The issue of perikaryal staining of neurons in Glu immunocytochemistry therefore seems closely related to the fact that 60-80% of Glu present in the CNS may belong to the metabolic pool (Fon-num, 1984) and, in spite of its obvious importance, it has not yet been studied experimentally.
The metabolism of Glu is complex, and particularly so when the relationship between Glu metabolism and its neurotransmitter function is considered. Several biosynthetic pathways are believed to produce releasable Glu: glutamine, tricarboxylic acid cycle constituents (such as a-ketoglutarate and malate), ornithine, and glucose (Erecinska and Silver, 1990; Hertz and Schousboe, 1988; Shank and Aprison, 1988; Fonnum, 1984) , but their relative contributions are still incompletely understood. Many studies, however, strongly suggest that the conversion of glutamine (Gln) to Glu catalyzed by phosphate-activated glutaminase (EC 3.5.1.2; PAG) plays a crucial role in the formation of releasable Glu (Ji et al., 1991; Sherman and Mott, 1986; Thanki et al., 1983; Reubi, 1980; Hamberger et al., 1979a.b; Hertz, 1979; Reubi et al., 1978; Bradford et al., 1978 Bradford et al., ,1983 . It has been calculated that PAG activity seems to be responsible for up to 75% of the Glu released in a calciumdependent manner (Hamberger et al., 1979a,b) . PAG is regulated by a variety of physiological activators and inhibitors and can be inhibited by several exogenous substances ( K v a " e et al., 1988) . Among the latter, the diazoketone 6-diazo-5-oxo-~-norleucine (DON) (Shapiro et al., 1979; Pinkus and Windmueller, 1977) has been shown to produce a large decrease in the acetate-derived, veratridine-released Glu from cerebellar slices (Nicklas, 1983) . More recently, Sherman and Mott (1986) reported that DON reduced the amount of Glu released in a calcium-dependent manner from cortical synaptosomes to about 20-30% of the control levels, without measurable effects on the release of y-amino-butyric acid (GABA), glycine, or serotonin. Furthermore, Storm-Mathisen et al. (1986) have shown that 6 mM DON prevents Glu-ergic nerve endings in hippocampal slices from sustaining Glu immunoreactivity during K' stimulation in the presence of precursor Glu. These data therefore suggest that DON is apotent and selective inhibitor of the enzyme responsible for the synthesis of most of the releasable Glu, and therefore offers an opportunity to study experimentally the issue of perikaryal staining in Glu immunocytochemistry.
In the present work, we have studied the effects of topical administration of low doses of DON on the perikaryal staining of cortical neurons of adult rats. The results show that DON application abolishes Glu, but not aspartate, immunoreactivity completely and in a dose-dependent manner in perikarya of cortical neurons and that this effect is reversible. Some ofthese results have been presented in abstract form (Conti and Minelli, 1991a,b) .
Materials and Methods
Experiments were performed on 26 xdult Sprague-Dawley rats of both sexes, weighing 200-250 g. All animals were anesthetized with chloral hydrate (12% in distilled water; 0.6-0.7 ml IP) and mounted on a stereotaxic frame.
In five animals, one or two injections (0.1-0.2 pl each) of a 1-mM solution of DON (Sigma, St Louis, MO; D2141) in physiological saline were administered in the parietal cerebral cortex via a glass micropipette (tip diameter 80-100 pm) glued to a Hamilton microsyringe. In the other rats (15). a small piece of gelfoam (2 x 3 mm; Spongostan standard, batch 63880; Ferrosan, Copenhagen, Denmark) soaked with 2 p1 of a solution containing DON (0.25-1 mM; pH 7.4) was applied directly on the pial surface. The following controls were performed (a) injection of 0.2-0.3 p1 of physiological saline 1.5-2 mm from the DON injection site; (b) an empty micropipette advanced through the cerebral cortex 1-2 mm from the DON injection site; and (c) a small piece of gelfoam soaked with 2 p1 of physiological saline applied to the contralateral cortex. In all animals, the cortical region selected for analysis included the somatosensory and/or the motor cortex, as indicated by the distinctive vascular pattern. In the animals in which DON was applied epipially, the gelfoam was kept in loco for 20-30 min before perfusion, while animals receiving DON injections were allowed to survive 20-120 min. At the time of sacrifice, all experimental animals (plus two additional rats used as controls) were deeply anesthetized and perfused through the ascending aorta with physiological saline (300 ml), followed by a fixative solution (500 ml) containing either 4% carbodiimide (CDI; Sigma, cat. C-1920) or 4% CDI and 4% paraformaldehyde (PF) in 0.1 M phosphate buffer (pH 7.4) by means of a peristaltic pump (Watson-Marlow 502s; 80 mllmin). Brains were removed and postfixed in 4% PF. Brains from animals perfused with CDI only were postfixed for several days, and those from animals perfused with both CDI and PF were post-fixed overnight. A coronal slab (about 5 mm thick) of cortex was cut and rinsed in 0.1 m phosphate buffer (pH 7.4), and blocks of tissue were obtained and cut in 25-pm thick sections on a vibratome. Sections were collected in PBS in serial groups of five. Of each series, one section was stained with 0.1% thionine, one was processed for Glu immunocytochemistry, one was reacted for cytochrome oxidase histochemistry, one was used for the immunocytochemical visualization of aspartate (Asp; two rats), and one was kept unprocessed for several days. The possible effect of DON on Asp immunoreactivity was studied to rule out nonspecific effects. In five rats, the DON-soaked piece of gelfoam was removed after 30 min. the cerebral cortex was rinsed several times with physiological saline, and the animals were allowed to survive for 5-10 days.
For immunocytochemistry, sections were rinsed in PBS and incubated for 15 min in normal sheep serum (NSS, 2 % in PBS) and then overnight in the primary antiserum (see below). On the following day, sections were rinsed in PBS, incubated in NSS, and immersed in the secondary antibody (biotinylated goat anti-rabbit; bGAR, Vector Laboratories, Burlingame, CA; cat. BA-1000, lot 90501; 1:200 in PBS) for ~1 hr. After incubation in bGAR, sections were rinsed again in PBS and incubated in a solution containing the ABC reagents (Vector; Vectastain ABC kit standard, cat. PK-4000) (Hsu et al., 1981) . Sections were then rinsed in PBS (two rinses, 15 min each) and incubated in 3,3'-diaminobenzidine (DAB, Sigma, 0.075% in 0.05 M Tris buffer, pH 7.6) and 0.002% of H202 for 5-8 min. Sections were finally rinsed in PBS, mounted on subbed slides, air-dried, coverslipped with DPX, and viewed on a Leitz microscope. Sections selected for cytochrome oxidase histochemistry were processed as described previously (Conti et al., l988a) .
The characterization of the antisera used in this study (482a at a dilution of 1:8000-1:12,000 for the anti-Glu serum and of 1:4000-1:6000 for the anti-Asp serum; 482b at a dilution of 1:5000-1:8000 for the Glu antiserum and 1:3000-1:6000 for the anti-Asp antiserum) and the pattern of immunoreactivity in the cerebral cortex haw been discussed in previous works (Hepler et al., 1988; Conti et al., 1987a Conti et al., ,b,1988b Conti et al., ,c,1989 . The antibodies were raised to glutaraldehyde-conjugated Glu (Hepler et al., 1988) , whereas previous studies have shown that the use of carbodiimide (and/or paraformaldehyde) gives a better signal-to-noise ratio Conti et al., 1987a) . It was therefore necessary to test whether staining with the antibodies could be abolished after adsorption with a conjugate in which Glu or Asp was linked to hemocyanin by carbodiimide. Conjugates were prepared in the following way. One-ml aliquots from each of the following solutions were combined: bovine serum albumin (BSA) 10 mg/ml, Glu or Asp 10 mglml. and CDI (same as used for fixation) 100 mglml. All reagents were from Sigma. The mixture was incubated at room temperature overnight under slow stirring, and subsequently dialyzed against distilled water for 24 hr. Finally, aliquots corresponding to about 2 mg of BSA were prepared and dried in a Speed-Vac. Examination of a series of sections processed as described above with primary anti-Glu serum incubated overnight with the different concentrations of CDI-Glu conjugate showed that the Glu but not the Asp staining was completely blocked by 175 pg of neuronsdisplaying an apparently full-sized nucleus in the plane of the section were selected (for details see Conti et al.. 1987a) .
Results
In the two untreated rats. the distribution and morphology of Glupositive neurons and axon terminals were similar to those previ-ously reported in the somatosensory cortex of rats (Conti et al., 1987a) . Many immunoreactive neurons were present in all cortical layers, except for Layer I, but were unevenly distributed. Labeled neurons were more numerous in Layers 11-111 and V-VI. The vast majority of Glu-positive neurons were pyramidal cells, even though some non-pyramidal neurons were also observed, mostly in Layers I1 and IV.
Intraparenchymal injections of DON produced clear and consistent effects on Glu immunolabeling. The cortical region surrounding the needle track was essentially devoid of Glu positive neurons and of dot-like elements that in previous studies were shown to be mostly immunoreactive axon terminals (Conti et al.. 1989; Dori et al.. 1989; DcFelipe et al.. 1988 ). This empty region extended for about 300-400 pm along the radial axis of the cortex and for com. MINELLI 200-300 pm along the tangential axis. In the neighboring regions. the morphology and distribution of Glu-positive neurons and terminals were comparable in all respects to the normal pattern dcscribed above. In some animals, as reported in Materials and Methods, additional penetrations were performed. either with an empty micropipette or with a physiological saline-filled micropipette through which 0.2-0.3 pl of saline was injected in the cerebral cortex. In both conditions, histological analysis failed to rcvcal significant variations in the pattern of Glu immunoreactivity. In adjacent sections stained with thioninc or processed for cytochrome oxidase histochemistry, the corresponding regions showed no changes in the morphology and number of neurons or in the pattern of cytochrome oxidase activity.
The effects of DON were most pronounced when it was applied on the pial surface. In the cases in which the chemical was used at a concentration of 1 mM, the underlying cortical region was virtually devoid of Glu-positive neurons and punaae, and the "empty" region was considerably wider than in the cases in which DON was injected intraparenchymally (Figure 1 ). Rare, pale Glu-positive neurons were occasionally observcd in the deepest l a p n (Figure 1) . The cortex immediately surrounding the affected region showed a regular pattern of Glu-positive neurons and axon terminals (Figure 1 ). In the cases in which DON was used at concentrations of 0.5 mM or0.25 mM. the halo of inhibition was still present (Figure  2) . although the inhibited region was considerably smaller than in the cases in which DON was used at 1 mM concentration and the degree of inhibition was not as strong (Figure 2) . Adjacent sections stained with thionine and the contralateral cortex (on which physiological saline-soaked gelfoam had bcen applied) were apparently unchanged with respect to the number and/or the morphol- ogy of neurons ( Figures 3A-3C) . Similarly, the pattern of cytochrome oxidase activity in adjacent sections was consistent with previous descriptions (Figure 4 ). In the animals in which sections adjacent to those processed for Glu were reacted with the anti-Asp serum, the morphology and laminar distribution of Asp-positive neurons ( Figure 5 ) were similar to that previously reported in rats and cats (Dori et al., 1989; Campistron et al., 1988; Conti et al., 1987b . Counts from five 500-pm wide sectors underneath DON application gave the following values; no neurons in Layer I, 129 in Layer 11, 106 in Layer 111, 38 in Layer IV, 96 in Layer V, and 45 in Layer VI, whereas counts from five analogous sectors of the contralateral hemisphere (controls) showed that the numbers of Asp-positive neurons were: 3 neurons in Layer I, 88 in Layer 11, 91 in Layer 111, 35 in Layer IV, 119 in Layer V. and 71 in Layer VI.
In the animals allowed to survive for 5-10 days after DON application, the pattern of Glu-positive neurons in the cortical region underneath DON application was normal in terms of morphology, laminar distribution, and number ( Figure 6A) . Counts from five 500-pm wide sectors showed that the number of Glupositive neurons was as follows: 3 neurons in Layer I, 33 in Layer 11, 57 in Layer 111, 15 in Layer IV. 77 in Layer V, and 55 in Layer VI (compare with Table I1 in Conti et al., 1987a) . Adjacent sections stained for cytochrome oxidase or with thionine showed a normal pattern ( Figures 6B and 6C) . 
Discussion
In the present experiments we have shown that intraparenchymal or epipial applications of DON completely and reversibly abolish Glu immunoreactivity in the perikarya of rat cortical neurons. Two issues must be addressed before we discuss the present findings in relation to the problem of perikaryal staining in Glu immunocytochemistry.
The first concerns the role of PAG in the synthesis of releasable Glu. As reported in the Introduction, a large body of experimental data obtained by a variety of methods supports the notion that PAG is a crucial although not exclusive enzyme for the synthesis of transmitter Glu (Ji et al., 1991; Sherman and Mott, 1986; Thanki et al., 1983; Ward et al., 1983; Reubi, 1980; Hamberger et al., 1979a,b; Hertz, 1979; Bradford et al., 1978 Bradford et al., ,1983 . These data have been recently confirmed by showing an elevation of KCI-and 4-aminopyridine-induced Glu release from synaptosomal preparations pre-incubated with glutamine (Sherman, 1991) . thus confuting the negative findings of McMahon and Nicholls (1990) .
The second concerns the specificity of DON inhibition of PAG activity. DON has been shown to inhibit PAG irreversibly in various tissues, both in vivo and in vitro, by interacting with the enzyme glutamine-binding site (Pinkus and Windmueller. 1977) . and to decrease the acetate-derived, veratridine-induced (Nicklas, 1983) and the calcium-dependent (Sherman and Mott, 1986 ) release of Glu. Furthermore, DON has no obvious effect on other enzymes involved in Glu synthesis, e.g.. aspartate aminotransferase (EC 2.6.1.1) (Zollner, 1990; Barman, 1985; Nicklas, 1983) . with the exception of y-glutamyltransferase (y-glutamyltranspeptidase, EC 2.3.2.2; see data and literature in Patel et al., 1977) whose role, if any, in synthesis of releasable Glu seems negligible (Shank and Aprison, 1988; Ottersen and Storm-Mathisen, 1984) . This evidence is corroborated by the present finding that DON does not affect Asp immunoreactivity. Furthermore, the demonstration that inhibition still occurred when DON was used at concentrations as low as 0.25 mM suggests that only the most sensitive enzymes are affected. The controls performed in the present experiments lack the resolution of chemical assays and therefore they do not exclude the possibility that DON induces some nonspecific effects. Nevertheless, they suggest some degree of specificity by showing that DON: (a) does not induce neuron death; (b) does not alter the pattern of cytochrome oxidase activity, which suggests that it does not interfere significantly with cellular metabolism; and (c) does not inhibit immunocytochemical visualization of Asp, which indicates that it does not block the key enzyme(s) for Asp biosynthesis. In addition, DON does not block substance P immunoreactivity in dorsal root ganglia and neuropeptide Y immunoreactivity in the cerebral cortex (Conti and Minelli, 1991a.b) . These data are validated by the demonstration that the effects of DON on cortical neurons are reversible, indicating that the chemical does not induce any significant change in the normal functioning of neurons. When the data gathered in the present experiments are considered together with the biochemical evidence available, it seems rea- sonable to regard the inhibition observed in the present experiments as a specific inhibition of PAG activity.
The present demonstration of a total disappearance of Glu immunoreactivity in cortical perikarya after administration of the PAG inhibitor DON could be interpreted as evidence that all the transmitter pool of Glu originates from glutamine. That this is not the case is proven by experimental evidence showing that [U-14C]glucose is used as precursor for releasable Glu (Hamberger et al., 1979a; Bradford et al., 1978; Potashner, 1978) and that, although quantitatively less important, ornithine also may be a precursor for releasable Glu (Daune and Seiler, 1988; Shank and Campbell, 1983; Yoneda et al., 1982; Roberts, 1981) . All this evidence suggests that there is a threshold for immunocytochemical staining, and it is conceivable that the threshold is reached (i.e., there is positive staining) only when the transmitter pool of Glu is added to the metabolic pool, and that the absence of a conspicuous amount of releasable Glu (that originated from glutamine) reduces the intracellular Glu concentration to subthreshold levels, thus resulting in negative staining.
Glu is synthesized at the nerve terminal (Fonnum, 1991) . and therefore the observation that Glu immunoreactivity results in intense perikaryal staining has been often interpreted as evidence that the metabolic pool of Glu contributes significantly to the overall picture in immunocytochemical preparations. By showing that Glu immunoreactivity in neuron perikarya disappears after DONinduced inhibition of PAG activity, the present results indicate that the fraction of perikaryal Glu immunoreactivity produced via glutaminase is critical for immunocytochemical visualization. In this context, it is worth noting that Storm-Mathisen et al. (1986) have shown that DON prevents the release of Glu produced via glutaminase from immunocytochemically stained nerve endings in hippocampal slices. The finding that the same compound induces disappearance of p e r h y a l Glu immunoreactivity and (at higher doses) prevents Glu release at the axon terminal could indicate that Glu immunoreactivities demonstrated in perikarya and in axon terminals share the same biosynthetic pathways. Whether the fraction of PAG-dependent Glu immunoreactivity that is critical for immunocytochemical visualization is produced via "perikaryal" or "synaptosomal" PAG (Aoki et al., 1991) is at present completely unknown, as is the possible role of eventual perikaryal high-affinity uptake sites. Whatever the mechanism(s) responsible for cell body staining, given the crucial role of PAG in the formation of "releasable" Glu Ui et al., 1991; Sherman and Mott, 1986; Thanki et al., 1983; Ward et al., 1983; Reubi, 1980; Hamberger et al., 1979a,b; Hertz, 1979; Bradford et al., 1978 Bradford et al., ,1983 , the results reported here give some strength to the hypothesis that, under our experimental conditions, Glu immunoreactivity in perikarya of cortical neurons might reflect the neurotransmitter pool of Glu (i.e., that Glu immunoreactivity in cell bodies might indeed be a marker of cortical neurons releasing Glu at their nerve terminals). In the cerebral cortex, this possibility is supported by the following observations: (a) the selectivity of staining, both at light and at electron microscopic levels. About 35% of all cortical neurons are Glu-positive, and they are virtually all pyramidal cells; furthermore, only a fraction of axon terminals forming asymmetric synaptic contacts are immunolabeled (Conti et al., 1987a (Conti et al., ,b.1989 DeFelipe et al., 1988) ; (b) the specificity of staining. Glu-positive neurons are almost completely segregated from Asp-and GABA-positive neurons (Conti et al.. 1987a.b ); (c) the lack of correlation between the distribution of Glu-positive neurons and that of neurons labeled by the mitochondrial enzyme cytochrome oxidase (Conti et al., 1987a) ; (d) the correlation between the results of immunocytochemical analysis and previous electrophysiological, anatomic, and pharmacological data (Conti, 1991) ; and (e) the results of the molecular characterization of neurotransmitter transporters, which are thought to play a major role in terminating synaptic transmission by rapidly transporting the neurotransmitter into the presynaptic nerve terminal and therefore to be presumably specific markers of chemically distinct neuronal populations. It was recently shown that three distinct complementary DNAs encode structurally related excitatory amino acid transporters Kanai and Hediger, 1992; Pines et al., 1992; Storck et al., 1992) . Of these, one (termed EAAC1) (Kanai 1 rnM, 30 min) . Normal pattern of (9) cytochrome oxidase activity and of (C) thionine staining in two sections adjacent to the one shown in A. Asterisks in A and C indicate the same blood vessel. Bar = 100 prn. and Hediger, 1992) seems to be largely neuronal, and in situ hybridization indicates that the distribution of EAACl transcripts in the cerebral cortex (see Figures 3C and 3D in Kanai and Hediger, 1992) is remarkably similar to that of Glu-immunoreactive neurons (Conti et al., 1987a; Otteaen and Storm-Mathisen, 1984; Storm-Mathisen et al., 1983) . Analogous conclusions have recently been obtained in the cerebellar climbing fiber system by Zhang et al. (1990) . Using a post-embedding immunogold procedure and semiquantitative analysis, they correlated the pattern of Glu immunoreactivity in neurons of the interior olive with the labeling of climbing fiber terminals and observed that Glu levels in axon terminals were comparable to those present in their parent cell bodies (whereas such a correlation could not be demonstrated for aspartate).
